HeartForce filed a patent application in the United States for monitoring patients after coronary angioplasty. The provisional patent was assigned the application number U.S. 63/459960. Meanwhile, the company will be conducting a one-year clinical study through the monitoring patients pre and post stent surgery
20
Mar 2023
Need to get in touch with the team? We’re all ears.
Contact us today.
This website (“Web Site”) is offered to you by HeartForce Medical Inc. (HeartForce), Vancouver, BC, Canada.
The following Terms of Use govern your access and use of this Web Site and its service. Also, specific terms and conditions may apply to specific content, data, materials, or information contained on or available through this Web Site (the “Content”) and to specific content, data, materials, or information you may upload, submit and/or publish to the Web Site (“User Content”) or transactions concluded through this Web Site.
The following Terms of Use govern your access and use of this Web Site and its service. Also, specific terms and conditions may apply to specific content, data, materials, or information contained on or available through this Web Site (the “Content”) and to specific content, data, materials, or information you may upload, submit and/or publish to the Web Site (“User Content”) or transactions concluded through this Web Site.